Publications by authors named "Kylie Haskins"

Article Synopsis
  • - The Biomarker Qualification Program was created by the FDA's CDER to speed up the use of promising biomarkers in drug development, starting with the qualification of seven safety biomarkers in 2008, including KIM-1 for detecting kidney damage in rats.
  • - This article reviews the application of KIM-1 in drug development and research, examining data from various sources such as FDA databases, ClinicalTrials.gov, and PubMed.
  • - Findings show that after KIM-1 was qualified, its use significantly increased in drug development programs analyzed by CDER and in subsequent research on kidney injury detection.
View Article and Find Full Text PDF

Cationic amphiphilic drugs and aminoglycoside antibiotics can induce phospholipidosis (PLD), an abnormal accumulation of phospholipids in lysosome-derived vesicles, in preclinical studies. The incidence of PLD in patients and its clinical relevance are difficult to assess without noninvasive biomarkers. Di-docosahexaenoyl bis(monoacylglycerol)phosphate (di-22:6-BMP) is a phospholipid that is enriched in lysosomal membranes and a proposed urinary biomarker of drug-induced PLD.

View Article and Find Full Text PDF

The endoplasmic reticulum stress response, also known as the unfolded protein response (UPR), has been implicated in the normal physiology of immune defense and in several disorders, including diabetes, cancer, and neurodegenerative disease. Here, we show that the apoptotic receptor CED-1 and a network of PQN/ABU proteins involved in a noncanonical UPR response are required for proper defense to pathogen infection in Caenorhabditis elegans. A full-genome microarray analysis indicates that CED-1 functions to activate the expression of pqn/abu genes.

View Article and Find Full Text PDF